uniQure’s (QURE) Outperform Rating Reaffirmed at Royal Bank of Canada

by · The Cerbat Gem

uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Royal Bank of Canada in a note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 65.47% from the stock’s previous close.

QURE has been the subject of several other reports. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group raised their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Finally, Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

View Our Latest Stock Report on QURE

uniQure Stock Up 3.2 %

Shares of NASDAQ:QURE traded up $0.45 during mid-day trading on Tuesday, hitting $14.50. 298,005 shares of the company traded hands, compared to its average volume of 1,274,328. The firm’s 50 day simple moving average is $12.22 and its 200 day simple moving average is $8.48. The firm has a market cap of $706.92 million, a P/E ratio of -2.92 and a beta of 0.41. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, equities analysts anticipate that uniQure will post -3.74 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of uniQure during the fourth quarter worth approximately $88,000. Geode Capital Management LLC grew its holdings in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares in the last quarter. Finally, American Century Companies Inc. increased its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 8,642 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Featured Articles